Two Sigma Advisers
MIRM icon

Two Sigma Advisers’s Mirum Pharmaceuticals MIRM Stock Holding History

Two Sigma Advisers’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-232,100
Closed -$18.3M – 1288
2025
Q4 		$18.3M Sell
232,100
-44,300
-16% -$3.18M 0.04% 378
2025
Q3 		$20.3M Buy
276,400
+105,000
+61% +$6.67M 0.04% 331
2025
Q2 		$8.72M Sell
171,400
-35,200
-17% -$1.57M 0.02% 551
2025
Q1 		$9.31M Buy
206,600
+32,200
+18% +$1.52M 0.02% 555
2024
Q4 		$7.21M Sell
174,400
-31,100
-15% -$1.3M 0.02% 578
2024
Q3 		$8.01M Buy
205,500
+25,600
+14% +$1.02M 0.02% 550
2024
Q2 		$6.15M Sell
179,900
-17,100
-9% -$448K 0.01% 687
2024
Q1 		$4.95M Sell
197,000
-139,300
-41% -$3.83M 0.01% 782
2023
Q4 		$9.93M Sell
336,300
-54,600
-14% -$1.65M 0.02% 530
2023
Q3 		$12.4M Buy
390,900
+328,300
+524% +$8.99M 0.03% 412
2023
Q2 		$1.62M Buy
62,600
+32,300
+107% +$859K ﹤0.01% 1306
2023
Q1 		$728K Sell
30,300
-49,500
-62% -$1.13M ﹤0.01% 1782
2022
Q4 		$1.56M Sell
79,800
-32,100
-29% -$635K ﹤0.01% 1367
2022
Q3 		$2.35M Sell
111,900
-46,100
-29% -$1.11M 0.01% 1088
2022
Q2 		$3.08M Sell
158,000
-45,800
-22% -$1.08M 0.01% 988
2022
Q1 		$4.49M Buy
203,800
+36,058
+21% +$736K 0.01% 838
2021
Q4 		$2.67M Buy
167,742
+74,242
+79% +$1.15M 0.01% 1048
2021
Q3 		$1.86M Buy
93,500
+11,700
+14% +$190K ﹤0.01% 1298
2021
Q2 		$1.41M Buy
81,800
+12,600
+18% +$226K ﹤0.01% 1474
2021
Q1 		$1.37M Buy
69,200
+46,100
+200% +$883K ﹤0.01% 1465
2020
Q4 		$403K Buy
+23,100
New +$454K ﹤0.01% 1946

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Two Sigma Advisers's MIRM Position: Q1 2026 in Review

Two Sigma Advisers sold out of Mirum Pharmaceuticals (MIRM) in Q1 2026, closing a stake of 232,100 shares — an estimated $18.3M sold.

Two Sigma Advisers first reported a position in MIRM in Q4 2020 and held it in 21 quarters. The position peaked at $20.3M in Q3 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Two Sigma Advisers reported no remaining Mirum Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 232,100 Mirum Pharmaceuticals shares in Q1 2026, an estimated $18.3M.
  • Two Sigma Advisers first reported a position in Mirum Pharmaceuticals in Q4 2020 and held it in 21 quarters.
  • Two Sigma Advisers's Mirum Pharmaceuticals position peaked at $20.3M in Q3 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.